Captor Therapeutics ®
FENG Projects
FENG.01.01-IP.01-1001/23
Project: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor - Stage II”.
The project is financed by European Funds for Smart Economy 2021-2027 (FENG), SMART Path.
The project involves the development of an oral drug/drug candidate for use in the treatment of patients with hepatocellular carcinoma (HCC). The project includes conducting preclinical studies and conducting Phase Ia clinical trials.
Purpose and planned outcomes of the project: Development of a drug candidate for the treatment of hepatocellular carcinoma, allowing the elimination of cancer cells, through induced degradation of an oncogenic transcription factor. The drug candidate will be tested in Phase I clinical trials.
Value of the project stage II: 12 351 378,40 zł
European Union financing 6 766 157,95 zł
FENG.01.01-IP.01-1002/23
Project:“Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies – stage II” (FENG.01.01-IP.01-1002/23)
The project is financed by European Funds for Smart Economy 2021-2027 (FENG), SMART Path.
The project involves design and development of an innovative drug candidate that induces MCL-1 protein degradation via the proteasomal pathway. The project includes conducting preclinical studies and Phase Ia clinical trials.
Purpose and planned outcomes of the project: To develop the dossier of the selected drug candidate for the treatment of cancers such as non-small lung cancer and triple negative breast cancer, along with toxicological and pharmacological data, and to conduct a Phase 1a clinical trial.
Value of the project stage II: 7 802 294,00 PLN
European Union financing: 4 976 940,75 PLN